R&D Contract with a U.S. Bio Venture
JW Group announced on Nov. 1 that it has signed a joint research contract with KURE.AI Therapeutics, a U.S. biotech venture company, to develop innovative anticancer therapies based on artificial intelligence (AI).
Under this contract, JW Pharmaceutical and JW CreaGene will start R&D activities for three new anticancer drugs using KURE.AI’s artificial intelligence and machine learning-based cancer patient genome analysis and biomarker search platform.
JW Pharmaceutical will discover a new small-molecule anticancer drug targeting immuno-cancer drug-resistant solid cancer patients together with KURE.AI. In addition, it will set up an intermediary clinical strategy to increase the clinical success rate of new anticancer drug candidates being developed by JW Pharmaceutical.
JW CreaGene, an R&D subsidiary of JW Shinyak, will collaborate with KURE.AI to derive new chimeric antigen receptor (CAR)-NK cell therapy candidates for the treatment of solid cancer. It plans to expand its pipeline of immune cell therapies, along with dendritic cell therapies and CAR-macrophage treatments, which are currently under research and development.